Advanced Gastroesophageal Cancer
Publication Date: January 4, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...atment
...gure 1. Immunotherapy and Targeted Therapy for Adv...
...t-line Therapy...
...1.1For HER2-negative patients with...
...1.2For HER2-negative patients with eso...
...1.3For patients with ESCC and PD-L1 CPS ≥1...
...mmendation 1.4For patients with ESCC, and PD-L...
...commendation 1.5For patients with HE...
...cond- or Third-line Thera...
Recommendation 2.1For patients with adva...
...2.2For HER2-positive patients with gastric or G...